Normally, a biotech hostile takeover is risky because the scientists (the “intellectual capital” as opposed to the IP) might leave after the merger closes. Astellas seems not to care about this, which makes me think they don’t ascribe much value to OSIP’s scientists.
News 
Market Data 
Discover 
AI
